All In Biotech

Free tool

FAERS Monitor: Ziextenzo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761045 or its brand name (Ziextenzo, Pegfilgrastim-Bmez). Reports on generic versions are filed under their own applications.

Reports

607

Serious

506

83% of reports

Hospitalization

239

Death reported

190

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death133
  • neutropenia49
  • off label use48
  • fatigue42
  • nausea38
  • vomiting37
  • drug ineffective36
  • sepsis34
  • back pain32
  • c-reactive protein increased29
  • pyrexia29
  • candida infection28
  • restlessness28
  • pleural effusion27
  • brain oedema26

Reports by year received

View as table
YearReports
20198
202046
202174
2022120
2023141
2024120
202577
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,552 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
brain oedemaSignal2671.549.11,735
candida infectionSignal2857.540.11,498
c-reactive protein increasedSignal2927.619.4719
restlessnessSignal2826.518.5663
pleural effusionSignal2715.410.6350
neutropeniaSignal4912.59.5510
sepsisSignal3410.67.6286
deathSignal1335.34.6486
back painSignal324.83.493
pyrexiaSignal292.92.035
vomitingSignal372.72.040
off label use481.91.420
fatigue421.91.417
nausea381.71.210
drug ineffective360.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.